DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024.

Revenue
+11.2%
EPS
0.00%
Free cash flow
−52.9%
Total debt
+0.31%

Quarter to September 2026, against a year earlier

79.91 4.55 −5.39%
Market cap
$31.5B
P/E
32.6×
Fwd P/E
31.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a

DexCom, Inc. (DXCM) Free cash flow margin

Alert me on Free cash flow margin

DexCom, Inc.'s free cash flow margin over the twelve months to 30 September 2026 was 21.5%, down 1.6 percentage points from fiscal 2025 (23.1%). Over the past ten years it has ranged from 0.09% (fiscal 2016) to 111.1% (fiscal 2021); the current reading is higher than 91% of that period. That is above the Medical Devices industry median of −3.88% and above the Healthcare sector median of 0.00%.

Free cash flow margin, annual

Embed this chart

Annual newest first

Period Free cash flow margin Change (points)
FY2025 23.1% 7.47
FY2024 15.6% 1.51
FY2023 14.1% 3.66
FY2022 10.5% (100.60)
FY2021 111.1% 96.71
FY2020 14.4% 5.25
FY2019 9.11% 3.67
FY2018 5.44% 1.82
FY2017 3.62% 3.53
FY2016 0.09% (3.82)

Against its own ten years

Low 0.09% High 111.1%
Ten-year median 10.5%
Current reading's percentile 91

Free cash flow margin against peers

What Free cash flow margin is

Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.

(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue

The full definition of Free cash flow margin →

More on DXCM